Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764703 | 0.90 | TACR1 (0.64) | TACR1 | |
| SCHEMBL30307065 | 0.90 | TACR1 (0.72) | TACR1 | |
| SCHEMBL23629620 | 0.90 | TACR1 (0.72) | TACR1 | |
| SCHEMBL2997671 | 0.90 | TACR1 (0.72) | TACR1 | |
| SCHEMBL6762526 | 0.89 | TACR1 (0.79) | TACR1 | |
| Water SCHEMBL7834521 | 0.89 | TACR1 (0.71) | TACR1 | |
| Hydrochloric Acid SCHEMBL7823238 | 0.89 | TACR1 (0.71) | TACR1 | |
| Hydrochloric Acid SCHEMBL7833330 | 0.88 | TACR1 (0.70) | TACR1 | |
| Oxalic Acid SCHEMBL8748967 | 0.88 | TACR1 (0.69) | TACR1 | |
| SCHEMBL6763282 | 0.86 | TACR1 (0.71) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030152626-A1 | New pharmaceutical compositions | NOVARTIS AG (CH) | 2003-08-14 | — | — | US | disclosed |
| US-20020156099-A1 | New pharmaceutical compositions | LANG STEFFEN (CH) | 2002-10-24 | — | — | US | disclosed |
| EP-1082119-A1 | MICROEMULSION PRECONCENTRATES CONTAINING A PIPERIDINE SUBSTANCE P ANTAGONIST | Novartis AG (CH) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061025-A1 | MICROEMULSION PRECONCENTRATES CONTAINING A PIPERIDINE SUBSTANCE P ANTAGONIST | NOVARTIS AG (CH) | 1999-12-02 | — | — | WO | disclosed |